Novo Nordisk CEO Maziar Mike Doustdar discusses demand for the Danish firm's weight-loss drug Wegovy and diabetes medication ...

Novo Nordisk said on Wednesday it had agreed a price under the U.S. Medicare scheme for semaglutide, the active ingredient in ...

Novo Nordisk lowers its 2025 profit forecast as new CEO Mike Doustdar faces rising competition, leadership changes, and a ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit and sales forecasts ...

(Reuters) -European shares hit a two-week low on Wednesday as elevated equity valuations continued to make investors nervous ...

The latest of those is a bid valued at up to $10 billion for U.S. obesity-drug developer Metsera, up from a previous $9 billion offer it originally made, as it tries to usurp an already agree-on deal ...

Dow Jones Top Company Headlines at 3 AM ET: Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs | Orsted ... Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer and acquire the development-stage drugmaker Metsera.

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

COPENHAGEN () -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the Danish ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.